MDGL241220C340000
- 10.20
- 0.000.00%
Madrigal Pharmaceuticals Newsroom
Sagimet Started at Outperform by Oppenheimer, MASH Drug Cited
Madrigal Pharmaceuticals Price Target Raised to $427 From $415 at JMP Securities
Insider Sale: Director at $MDGL (MDGL) Sells 520 Shares
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,135,122, According to a Recent SEC Filing
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Path To Profitability
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
Express News | Form 144 | Madrigal Pharmaceuticals(MDGL.US) Director Proposes to Sell 3.23 Million in Common Stocks
Top 3 Health Care Stocks That May Dip This Month
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?
Novo Semaglutide Data in MASH Could Negatively Impact Madrigal's Rezdiffra
Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $400
Madrigal Pharmaceuticals Price Target Raised to $400 From $350 at Oppenheimer
Trump Media Saw the Largest Increase in Short Interest in October
Express News | Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Express News | Watching Madrigal Pharmaceuticals; Traders Circulate Unconfirmed Rumor From M&A Blog That The Co May Be Seeing Takeover Interest
Paulson & Co. Exits AngloGold Ashanti, Boosts Madrigal Pharma Among Q3 Moves
Express News | Rtw Investments, LP Reports 9.2% Passive Stake in Madrigal Pharmaceuticals Inc as of Sept 30, 2024- SEC Filing
Sagimet Draws Buy at UBS on MASH Opportunity